Tämä sivu käännettiin automaattisesti, eikä käännösten tarkkuutta voida taata. Katso englanninkielinen versio lähdetekstiä varten.

Nipokalimabin teho- ja turvallisuustutkimus aikuisilla, joilla on krooninen tulehduksellinen demyelinisoiva polyneuropatia (CIDP)

maanantai 2. marraskuuta 2026 päivittänyt: Janssen Research & Development, LLC

Vaihe 2/3, monivaiheinen, monikeskus, satunnaistettu, kaksoissokkoutettu, lumekontrolloitu rinnakkaisryhmävieroitustutkimus kroonista tulehduksellista demyelinisoivaa polyneuropatiaa (CIDP) sairastaville aikuisille annetun nipokalimabin tehon ja turvallisuuden arvioimiseksi

The main purpose of this study is to evaluate the safety and efficacy of nipocalimab compared to placebo in delaying relapse in adults with chronic inflammatory demyelinating polyneuropathy (CIDP) who initially respond to nipocalimab in Stage A.

Tutkimuksen yleiskatsaus

Opintotyyppi

Interventio

Ilmoittautuminen (Arvioitu)

201

Vaihe

  • Vaihe 2
  • Vaihe 3

Laajennettu käyttöoikeus

Ei tilapäisesti saatavilla kliinisen tutkimuksen ulkopuolella. Katso laajennettu käyttöoikeustietue.

Yhteystiedot ja paikat

Tässä osiossa on tutkimuksen suorittajien yhteystiedot ja tiedot siitä, missä tämä tutkimus suoritetaan.

Opiskeluyhteys

Opiskelupaikat

      • Buenos Aires, Argentiina, C1199ABB
        • Aktiivinen, ei rekrytointi
        • Hospital Italiano de Buenos Aires
      • Buenos Aires, Argentiina, C1428AQK
        • Rekrytointi
        • Instituto Fleni
      • Buenos Aires, Argentiina, C1428
        • Valmis
        • Hospital Gral Agudos Ignacio Pirovano
      • Rosario, Argentiina, 2900
        • Rekrytointi
        • INECO Neurociencias Orono
      • Melbourne, Australia, 3004
        • Valmis
        • The Alfred Hospital
      • Parkwood, Australia, 4215
        • Valmis
        • Gold Coast University Hospital
      • Alicante, Espanja, 03010
        • Aktiivinen, ei rekrytointi
        • Hosp. Gral. Univ. de Alicante
      • Barcelona, Espanja, 8035
        • Valmis
        • Hosp Univ Vall D Hebron
      • Bilbao, Espanja, 48013
        • Aktiivinen, ei rekrytointi
        • Hosp. Univ. de Basurto
      • Donostia / San Sebastian, Espanja, 20014
        • Valmis
        • Hosp. Univ. Donostia
      • Madrid, Espanja, 28040
        • Valmis
        • Hosp. Clinico San Carlos
      • Seville, Espanja, 41009
        • Aktiivinen, ei rekrytointi
        • Hosp. Virgen Macarena
      • Seoul, Etelä -Korea, 05030
        • Valmis
        • Konkuk University Medical Center
      • Seoul, Etelä -Korea, 02447
        • Valmis
        • Kyunghee University Medical Center
      • Seoul, Etelä -Korea, 135-710
        • Valmis
        • Samsung Medical Center
      • Catania, Italia, 95123
        • Valmis
        • Azienda Ospedaliero-Universitaria Policlinico di Catania
      • Genova, Italia, 16132
        • Valmis
        • Azienda Ospedaliera Universitaria San Martino di Genova
      • Milan, Italia, 20144
        • Valmis
        • Casa di Cura del Policlinico
      • Milan, Italia, 20133
        • Valmis
        • Istituto Neurologico Carlo Besta
      • Naples, Italia, 80131
        • Aktiivinen, ei rekrytointi
        • Azienda Ospedaliera di Rilievo Nazionale A Cardarelli
      • Orbassano, Italia, 10043
        • Valmis
        • Aou San Luigi Gonzaga
      • Pavia, Italia, 27100
        • Valmis
        • Fondazione Istituto Neurologico Casimiro Mondino
      • Roma, Italia, 00168
        • Valmis
        • Fondazione Policlinico Universitario A Gemelli IRCCS
      • Rozzano, Italia, 20086
        • Valmis
        • IRCCS Istituto Clinico Humanitas
      • Asahikawa, Japani, 070-0901
        • Aktiivinen, ei rekrytointi
        • National Hospital Organization Asahikawa Medical Center
      • Bunkyō City, Japani, 113 8519
        • Aktiivinen, ei rekrytointi
        • Institute of Science Tokyo Hospital
      • Chiba, Japani, 260-8677
        • Valmis
        • Chiba University Hospital
      • Hamamatsu, Japani, 430-8558
        • Aktiivinen, ei rekrytointi
        • Seirei Hamamatsu General Hospital
      • Isehara, Japani, 259-1193
        • Aktiivinen, ei rekrytointi
        • Tokai University Hospital
      • Kobe, Japani, 650 0047
        • Valmis
        • Kobe City Medical Center General Hospital
      • Kodaira-shi, Japani, 187-8551
        • Aktiivinen, ei rekrytointi
        • National Center of Neurology and Psychiatry
      • Koshigaya, Japani, 343-8555
        • Aktiivinen, ei rekrytointi
        • Saitama Medical Center
      • Kumamoto, Japani, 860-8556
        • Valmis
        • Kumamoto University Hospital
      • Nagoya, Japani, 466-8560
        • Aktiivinen, ei rekrytointi
        • Nagoya University Hospital
      • Nagoya, Japani, 455-8530
        • Aktiivinen, ei rekrytointi
        • Chubu Rosai Hospital
      • Osaka Sayama Shi, Japani, 589 8511
        • Valmis
        • Kindai University Hospital
      • Sendai, Japani, 983-8520
        • Aktiivinen, ei rekrytointi
        • National Hospital Organization Sendai Medical Center
      • Shimotsuga Gun, Japani, 321 0293
        • Valmis
        • Dokkyo Medical University Hospital
      • Shinjuku-ku, Japani, 162-8666
        • Valmis
        • Tokyo Women's Medical University Hospital
      • Tenri, Japani, 632-0015
        • Valmis
        • Tenri Hospital
      • Toon-shi, Japani, 791-0295
        • Valmis
        • Ehime University Hospital
      • Toyama, Japani, 930-0194
        • Valmis
        • Toyama University Hospital
      • Ube, Japani, 755-8505
        • Valmis
        • Yamaguchi University Hospital
      • Ottawa, Kanada, K1N 6N5
        • Rekrytointi
        • The Ottawa Hospital Ottawa NeuroMuscular Centre
      • Beijing, Kiina, 100191
        • Valmis
        • Peking University Third Hospital
      • Beijing, Kiina, 100034
        • Valmis
        • Peking University First Hospital
      • Beijing, Kiina, 100053
        • Aktiivinen, ei rekrytointi
        • Xuanwu Hospital ,Capital Medical University
      • Beijing, Kiina, 100070
        • Aktiivinen, ei rekrytointi
        • Beijing Tiantan Hospital, Capital Medical University
      • Changchun, Kiina, 130021
        • Aktiivinen, ei rekrytointi
        • The First Hospital of Jilin University
      • Changsha, Kiina, 410008
        • Valmis
        • Xiangya Hospital Central South University
      • Changsha, Kiina, 410008
        • Aktiivinen, ei rekrytointi
        • The Third Xiangya Hospital of Central Sourth University
      • Chengdu, Kiina, 610072
        • Valmis
        • Sichuan Provincial Peoples Hospital
      • Chifeng, Kiina, 024000
        • Valmis
        • Chifeng Municipal Hospital
      • Fuzhou, Kiina, 350001
        • Aktiivinen, ei rekrytointi
        • Fujian Medical University Union Hospital
      • Guangzhou, Kiina, 510080
        • Aktiivinen, ei rekrytointi
        • The First Affiliated Hospital Sun Yat sen University
      • Jinan, Kiina, 250012
        • Aktiivinen, ei rekrytointi
        • Qilu Hospital of Shandong University
      • Jinan, Kiina, 250014
        • Valmis
        • Qianfoshan hospital of Shandong Province
      • Nanchang, Kiina, 330006
        • Aktiivinen, ei rekrytointi
        • The First Affiliated Hospital of NanChang University
      • Shanghai, Kiina, 200336
        • Valmis
        • Tong Ren Hospital Shanghai Jiao Tong University school of medicine
      • Shanghai, Kiina, 200040
        • Aktiivinen, ei rekrytointi
        • Huashan Hospital Fudan University
      • Wuhan, Kiina, 430023
        • Valmis
        • Renmin Hospital of Wuhan University
      • Xi'an, Kiina, 710032
        • Valmis
        • Tangdu hospital the Fourth Military Medical
      • Xi'an, Kiina, 710075
        • Aktiivinen, ei rekrytointi
        • Xi 'an GaoXin Hospital
      • Floridablanca, Kolumbia, 681004
        • Valmis
        • Fundación Cardiovascular de Colombia - Instituto del Corazón Floridablanca
      • Medellín, Kolumbia, 50021
        • Aktiivinen, ei rekrytointi
        • Instituto Neurológico de Colombia
      • Athens, Kreikka, 12462
        • Rekrytointi
        • Attikon General Hospital of Athens
      • Athens, Kreikka, 11527
        • Valmis
        • Papageorgiou General Hospital Of Thessaloniki
      • Pátrai, Kreikka, 26504
        • Valmis
        • Patras University Hospital
      • Thessaloniki, Kreikka, 54636
        • Rekrytointi
        • Ahepa Hospital Aristotle University of Thessaloniki
      • Monterrey, Meksiko, 64710
        • Valmis
        • i Can Oncology Center
      • Tlalnepantla, Meksiko, 54055
        • Rekrytointi
        • Clinical Research Institute S.C.
      • Almada, Portugali, 2805-267
        • Aktiivinen, ei rekrytointi
        • Hospital Garcia de Orta
      • Braga, Portugali, 4710-243
        • Valmis
        • Hospital de Braga
      • Porto, Portugali, 4200 319
        • Aktiivinen, ei rekrytointi
        • Centro Hospitalar de Sao Joao Epe
      • Chorzów, Puola, 41 500
        • Valmis
        • Centrum Medyczne
      • Krakow, Puola, 30 539
        • Valmis
        • Specjalistyczne Gabinety Lekarskie
      • Lublin, Puola, 20 093
        • Valmis
        • Prywatny Gabinet Lekarski
      • Poznan, Puola, 61 731
        • Aktiivinen, ei rekrytointi
        • Clinical Research Center sp z o o MEDIC R s k
      • Bordeaux, Ranska, 33000
        • Valmis
        • CHU Bordeaux
      • Bron, Ranska, 69699
        • Valmis
        • Hospices Civils de Lyon HCL
      • Le Kremlin-Bicêtre, Ranska, 94270
        • Aktiivinen, ei rekrytointi
        • Hopital de Bicetre
      • Marseille, Ranska, 13385
        • Aktiivinen, ei rekrytointi
        • Hopital de la Timone
      • Nice, Ranska, 06000
        • Aktiivinen, ei rekrytointi
        • Hopital PASTEUR
      • Nîmes, Ranska, 30029
        • Aktiivinen, ei rekrytointi
        • CHU Nimes Hopital Caremeau
      • Paris, Ranska, 75013
        • Valmis
        • Hopital de la Pitie Salpetriere
      • Paris, Ranska, 75019
        • Valmis
        • Fondation Adolphe de Rothschild Hospital
      • Strasbourg, Ranska, 67200
        • Aktiivinen, ei rekrytointi
        • CHRU Strasbourg
      • Berlin, Saksa, 13347
        • Aktiivinen, ei rekrytointi
        • Judisches Krankenhaus Berlin
      • Bochum, Saksa, 44791
        • Valmis
        • St. Josef-Hospital, Ruhr-Universität Bochum
      • Halle, Saksa, 6120
        • Aktiivinen, ei rekrytointi
        • Städtisches Krankenhaus Martha-Maria Halle-Dölau gGmbH
      • Hanover, Saksa, 30625
        • Aktiivinen, ei rekrytointi
        • Medizinische Hochschule Hannover
      • Leipzig, Saksa, 4103
        • Valmis
        • Universitaetsklinikum Leipzig
      • Potsdam, Saksa, 14471
        • Valmis
        • St Josefs Krankenhaus Potsdam Sanssouci
      • Kaohsiung City, Taiwan, 88301
        • Valmis
        • Kaohsiung Chang Gung Memorial Hospital
      • Taipei, Taiwan, 100
        • Aktiivinen, ei rekrytointi
        • National Taiwan University Hospital
      • Taipei, Taiwan, 111
        • Aktiivinen, ei rekrytointi
        • Shin Kong Wu Ho Su Memorial Hospital
      • Hradec Králové, Tšekki, 500 05
        • Aktiivinen, ei rekrytointi
        • Fakultni nemocnice Hradec Kralove
      • Ostrava, Tšekki, 708 52
        • Valmis
        • Fakultni Nemocnice Ostrava
      • Pardubice, Tšekki, 53203
        • Valmis
        • Pardubicka krajska nemocnice a s
      • Birmingham, Yhdistynyt kuningaskunta, B15 2TH
        • Valmis
        • University Hospitals Birmingham NHS Foundation Trust
      • Devon, Yhdistynyt kuningaskunta, EX2 5DW
        • Valmis
        • Royal Devon & Exeter Hospital
      • Glasgow, Yhdistynyt kuningaskunta, G514TF
        • Aktiivinen, ei rekrytointi
        • NHS Greater Glasgow and Clyde
      • London, Yhdistynyt kuningaskunta, NW3 2QG
        • Valmis
        • Royal Free Hospital
      • Sheffield, Yhdistynyt kuningaskunta, S10 2 JF
        • Aktiivinen, ei rekrytointi
        • Sheffield Teaching Hospitals NHS Foundation Trust
    • Colorado
      • Centennial, Colorado, Yhdysvallat, 80112
        • Aktiivinen, ei rekrytointi
        • IMMUNOe Health and Research Centers
    • Florida
      • Coral Springs, Florida, Yhdysvallat, 33067
        • Valmis
        • Healthcare Innovations Institute Inc
      • Maitland, Florida, Yhdysvallat, 32751
        • Valmis
        • Neurology Associates PA
      • Miami, Florida, Yhdysvallat, 33136
        • Aktiivinen, ei rekrytointi
        • ALS Center at the University of Miami
    • Georgia
      • Augusta, Georgia, Yhdysvallat, 30912
        • Valmis
        • Augusta University
    • Kansas
      • Kansas City, Kansas, Yhdysvallat, 66160
        • Valmis
        • University of Kansas Medical Center
    • Maryland
      • Baltimore, Maryland, Yhdysvallat, 21287
        • Valmis
        • Johns Hopkins Hospital
    • Massachusetts
      • Boston, Massachusetts, Yhdysvallat, 02111
        • Valmis
        • Boston Clinical Trials
    • Michigan
      • Royal Oak, Michigan, Yhdysvallat, 48073
        • Valmis
        • Beaumont Hospital Royal Oak
    • Missouri
      • Kansas City, Missouri, Yhdysvallat, 64128
        • Valmis
        • Kansas City Veterans Affairs Medical Center
    • New York
      • New York, New York, Yhdysvallat, 10032
        • Valmis
        • The Neurological Institute of New York
      • Patchogue, New York, Yhdysvallat, 11772
        • Valmis
        • South Shore Neurologic Associates - Patchogue
    • North Carolina
      • Charlotte, North Carolina, Yhdysvallat, 28204
        • Valmis
        • The Neurological Institute, PA
    • Ohio
      • Cleveland, Ohio, Yhdysvallat, 44195
        • Aktiivinen, ei rekrytointi
        • Cleveland Clinic Main Campus
    • Texas
      • Austin, Texas, Yhdysvallat, 78756
        • Valmis
        • Austin Neuromuscular Center
    • Wisconsin
      • Milwaukee, Wisconsin, Yhdysvallat, 53215
        • Aktiivinen, ei rekrytointi
        • Advocate Health - Aurora St. Luke's Medical Center

Osallistumiskriteerit

Tutkijat etsivät ihmisiä, jotka sopivat tiettyyn kuvaukseen, jota kutsutaan kelpoisuuskriteereiksi. Joitakin esimerkkejä näistä kriteereistä ovat henkilön yleinen terveydentila tai aiemmat hoidot.

Kelpoisuusvaatimukset

Opintokelpoiset iät

18 vuotta ja vanhemmat (Aikuinen, Vanhempi Aikuinen)

Hyväksyy terveitä vapaaehtoisia

Ei

Sukupuolet, jotka voivat opiskella

Kaikki

Kuvaus

Inclusion Criteria:

  • Adults greater than or equal to (>=) 18 years of age at the time of consent and as applicable, must also meet the legal age of consent in the jurisdiction in which the study is taking place
  • Diagnosed with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) according to criteria of the European Academy of Neurology/Peripheral Nerve Society (EAN/PNS) 2021, progressing or relapsing forms. CIDP diagnosis to be adjudicated by independent committee during screening period
  • Inflammatory Neuropathy Cause and Treatment (INCAT) disability score between 2 and 9 at the Run-In Baseline visit for participants entering Run-In, or Stage A Baseline visit for participants directly entering Stage A. Participants with an INCAT score of 2 at trial entry must have this score exclusively from the leg disability score
  • Fulfilling any of the following treatment conditions: a) Currently treated with oral corticosteroids (CS) less than or equal to (<=) 20 milligrams (mg)/day; or b) Currently treated with pulsed CS, and/or intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) and the participant is willing to discontinue no later than the run-in baseline visit; or c) Currently treated with oral CS greater than (>) 20 mg/day and the participant is willing to taper to <=20 mg/day during the run-in period; or d) Without previous treatment (treatment naive); or treatment with CS and/or IVIg or SCIg discontinued at least 3 months prior to screening (untreated)
  • Active disease as determined by CIDP Disease Activity Status (CDAS) score >= 3
  • Other protocol-defined inclusion criteria will apply

Exclusion Criteria:

  • Has a history of severe and/or uncontrolled hepatic (example, viral/alcoholic/autoimmune hepatitis/cirrhosis and/or metabolic liver disease), gastrointestinal, renal, pulmonary, cardiovascular, psychiatric, neurological or musculoskeletal disorder, hypertension and/or any other medical or uncontrolled autoimmune disorder(s) (example, diabetes mellitus) or clinically significant abnormalities in screening laboratory that, might interfere with the participants full participation in the study, or might jeopardize the safety of the participant or the validity of the study results
  • Pure sensory CIDP or chronic immune sensory polyradiculopathy (CISP) (EAN/PNS definition)
  • Any other disease that could better explain the participant's signs and symptoms, such as significant persisting neurological deficits from stroke or central nervous system (CNS) trauma or peripheral neuropathy from another cause such as connective tissue disease or systemic lupus erythematosus
  • Polyneuropathy of other causes, including the following: Multifocal motor neuropathy (MMN); Monoclonal gammopathy of uncertain significance with antimyelin associated glycoprotein (anti-MAG) immunoglobulin M (IgM) antibodies; Hereditary motor neuropathy; Hereditary neuropathy with liability to pressure palsies (HNPP); Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein and skin change syndromes; Lumbosacral radiculoplexus neuropathy; Polyneuropathy most likely due to diabetes mellitus; Polyneuropathy most likely due to systemic illnesses; Drug- or toxin-induced polyneuropathy Note: A concomitant polyneuropathy of other causes (example, a mild, stable diabetic polyneuropathy) is not necessarily exclusionary if chronic inflammatory demyelinating polyneuropathy (CIDP) is confirmed as the main diagnosis, as determined by the investigator and confirmed by the adjudication committee
  • Has known allergies, hypersensitivity, or intolerance to nipocalimab or its excipients
  • Other protocol-defined exclusion criteria will apply

Opintosuunnitelma

Tässä osiossa on tietoja tutkimussuunnitelmasta, mukaan lukien kuinka tutkimus on suunniteltu ja mitä tutkimuksella mitataan.

Miten tutkimus on suunniteltu?

Suunnittelun yksityiskohdat

  • Ensisijainen käyttötarkoitus: Hoito
  • Jako: Satunnaistettu
  • Inventiomalli: Rinnakkaistehtävä
  • Naamiointi: Kaksinkertainen

Aseet ja interventiot

Osallistujaryhmä / Arm
Interventio / Hoito
Kokeellinen: Nipocalimab

Participants in Stage A (Open-label) will receive a loading dose of nipocalimab (Dose 1) intravenous (IV) infusion on Day 1, followed by nipocalimab (Dose 2) IV infusion once every 2 weeks (q2w) from Week 2 to Week 12. Participants who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive nipocalimab (Dose 2) IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.

Nipocalimab will be administered intravenously.

Muut nimet:
  • JNJ-80202135
  • M281
Placebo Comparator: Placebo

Participants receiving nipocalimab in Stage A and who demonstrate evidence of clinical improvement in Stage A (responders) will enter Stage B (Double-blind) and receive placebo IV infusion q2w starting on Day 1 up to Week 52. After completion of Stage B or discontinuation from Stage B due to relapse, participants will have the option to enter the open label extension (OLE) phase and receive nipocalimab (Dose 2) IV infusion q2w starting on OLE Day 1 until 2 years after marketing authorization in a participant's local country or until nipocalimab becomes available commercially or via other continued access program, whichever comes first.

Placebo will be administered intravenously.

Mitä tutkimuksessa mitataan?

Ensisijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Stage B: Time to First Occurrence of a Relapse Event
Aikaikkuna: Up to 52 weeks

Stage B time to first occurrence of a relapse event will be reported.

Up to 52 weeks

Toissijaiset tulostoimenpiteet

Tulosmittaus
Toimenpiteen kuvaus
Aikaikkuna
Stage A: Time to Initial Confirmed Evidence of Clinical Improvement (ECI)
Aikaikkuna: 12 weeks

Time to initial confirmed ECI will be reported.

12 weeks
Stage A: Percentage of Responders as Determined by ECI
Aikaikkuna: 12 weeks

Stage A percentage of responders as determined by ECI will be reported.

12 weeks
Stage A: Change from Baseline Over Time in Adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) Disability Scale Score
Aikaikkuna: Baseline to 12 weeks

Change from Stage A baseline over time in adjusted INCAT disability scale score will be reported. The INCAT disability scale is a clinician-rated assessment that measures activity limitation and degree of functional disability. The INCAT scale is an ordinal scale scored from 0 to 10, with higher scores indicating more disability.

Baseline to 12 weeks
Stage A: Change from Stage A Baseline Over Time in Medical Research Council (MRC) Muscle Grading Scale Sum Score
Aikaikkuna: Baseline to 12 weeks

Change from Stage A baseline over time in MRC muscle grading scale sum score will be reported. The MRC muscle grading scale is a clinician-rated outcome that provides a strength rating (on a scale from 0 [no visible contraction] to 5 [normal]) in 6 muscles collected bilaterally: deltoid, biceps, wrist extensors, iliopsoas, quadriceps, tibialis anterior. Lower scores indicate greater impairment.

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Inflammatory Rasch-Built Overall Disability Scale (I-RODS) Centile Score
Aikaikkuna: Baseline to 12 weeks

Change from Stage A baseline over time in I-RODS centile score will be reported. The I-RODS comprises of 24 items representing common daily activities that address upper and lower limb disability and range in difficulty from very easy to very difficult. Lower scores indicate greater activity and social participation limitations.

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Aikaikkuna: Baseline to 12 weeks

Change from Stage A baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Baseline to 12 weeks
Stage A: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Aikaikkuna: Baseline to 12 weeks

Change from Stage A baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Baseline to 12 weeks
Stage B: Time to First Adjusted INCAT Disability Scale Score Deterioration Relative to Baseline
Aikaikkuna: Up to 52 weeks

Time to first adjusted INCAT disability scale score deterioration relative to Stage B baseline will be reported.

Up to 52 weeks
Stage B: Time to First Switch to Intravenous Immunoglobulin (IVIg) or Other Standard of Care (SoC) as a Result of Investigator-assessed Lack of Efficacy as Confirmed by an Independent RAC Relative to Baseline
Aikaikkuna: Up to 52 weeks

Time to first switch to IVIg or other SoC as a result of investigator-assessed lack of efficacy as confirmed by an independent Relapse Adjudication Committee (RAC) relative to Stage B baseline will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in Adjusted INCAT Disability Score
Aikaikkuna: Up to 52 weeks

Change from Stage B baseline over time in adjusted INCAT disability score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in MRC Muscle Grading Scale Sum Score
Aikaikkuna: Up to 52 weeks

Change from Stage B baseline over time in MRC Muscle Grading Scale Sum score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in I-RODS Centile Score
Aikaikkuna: Up to 52 weeks

Change from Stage B baseline over time in I-RODS centile score will be reported.

Up to 52 weeks
Stage B: Change from Baseline Over Time in Mean Grip Strength (Dominant Hand)
Aikaikkuna: Up to 52 weeks

Change from Stage B baseline over time in mean grip strength (dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Up to 52 weeks
Stage B: Change from Baseline Over Time in Mean Grip Strength (Non-Dominant Hand)
Aikaikkuna: Up to 52 weeks

Change from Stage B baseline over time in mean grip strength (non-dominant hand) will be reported. Grip Strength is a quantifiable, objective performance outcome measure of hand strength, which can be measured using various devices (for example, Martin Vigorimeter and Jamar Dynamometer).

Up to 52 weeks
Stage B: Number of Participants with Binary Response Endpoint Satisfying all 4 Conditions: a) An Improved Adjusted INCAT Disability Score Compared to Baseline; b) Not Relapsing; c) Not Switching to SoC; d) Not Discontinuing Treatment
Aikaikkuna: Up to 52 weeks

Number of participants with Binary response endpoint satisfying all 4 conditions: a) an improved adjusted INCAT Disability Score compared to Stage B baseline; b) not relapsing; c) not switching to SoC; d) not discontinuing treatment, will be reported.

Up to 52 weeks
Percentage of Participants with Treatment-emergent Adverse Events (TEAEs)
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks

An adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment

Stage A: 12 weeks; Stage B: Up to 52 weeks
Percentage of Participants with Serious Adverse Events (SAEs)
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks

SAE is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly/birth defect; suspected transmission of any infectious agent via a medicinal product or medically important.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Electrocardiogram (ECG) Values Over Time
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in ECG values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Vital Signs Values Over Time
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in vital signs values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Change in Clinical Laboratory Values Over Time
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with change in clinical laboratory values over time will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant ECG Abnormalities
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant ECG abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant Vital Signs Abnormalities
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant vital signs abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Clinically Significant Clinical Laboratory Abnormalities
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with clinically significant clinical laboratory abnormalities will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Percentage of Participants with Suicidal Ideation or Suicidal Behavior based on the Columbia-Suicide Severity Rating Scale (C-SSRS)
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks

Percentage of participants with suicidal ideation or suicidal behavior based on the C-SSRS will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Serum Nipocalimab Concentrations Over Time in Participants Receiving Active Study Intervention
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks

Serum nipocalimab concentrations over time in participants receiving active study intervention will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Anti-drug Antibodies (ADA) to Nipocalimab
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with ADA to Nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Titers of ADA to Nipocalimab
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks

Titers of ADA to nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Number of Participants with Neutralizing Antibodies (NAb) to Nipocalimab
Aikaikkuna: Stage A: 12 weeks; Stage B: Up to 52 weeks

Number of participants with NAb to Nipocalimab will be reported.

Stage A: 12 weeks; Stage B: Up to 52 weeks
Change from Baseline in Total Serum Immunoglobulin (IgG) Concentrations Levels Over Time
Aikaikkuna: Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks

Change from baseline in total serum IgG concentrations levels over time will be reported.

Stage A: Baseline to 12 weeks; Stage B: Baseline up to 52 weeks

Yhteistyökumppanit ja tutkijat

Täältä löydät tähän tutkimukseen osallistuvat ihmiset ja organisaatiot.

Tutkijat

  • Opintojohtaja: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Opintojen ennätyspäivät

Nämä päivämäärät seuraavat ClinicalTrials.gov-sivustolle lähetettyjen tutkimustietueiden ja yhteenvetojen edistymistä. National Library of Medicine (NLM) tarkistaa tutkimustiedot ja raportoidut tulokset varmistaakseen, että ne täyttävät tietyt laadunvalvontastandardit, ennen kuin ne julkaistaan ​​julkisella verkkosivustolla.

Opi tärkeimmät päivämäärät

Opiskelun aloitus (Todellinen)

Perjantai 23. syyskuuta 2022

Ensisijainen valmistuminen (Arvioitu)

Tiistai 15. joulukuuta 2026

Opintojen valmistuminen (Arvioitu)

Tiistai 11. heinäkuuta 2028

Opintoihin ilmoittautumispäivät

Ensimmäinen lähetetty

Torstai 7. huhtikuuta 2022

Ensimmäinen toimitettu, joka täytti QC-kriteerit

Torstai 7. huhtikuuta 2022

Ensimmäinen Lähetetty (Todellinen)

Torstai 14. huhtikuuta 2022

Tutkimustietojen päivitykset

Viimeisin päivitys julkaistu (Todellinen)

Tiistai 3. marraskuuta 2026

Viimeisin lähetetty päivitys, joka täytti QC-kriteerit

Maanantai 2. marraskuuta 2026

Viimeksi vahvistettu

Sunnuntai 1. marraskuuta 2026

Lisää tietoa

Tähän tutkimukseen liittyvät termit

Muut tutkimustunnusnumerot

  • CR109195
  • 80202135CDP3001 (Muu tunniste: Janssen Research & Development, LLC)
  • 2021-003234-37 (EudraCT-numero)
  • 2023-508425-28-00 (Rekisterin tunniste: EUCT number)
  • 2023 (Yhdysvaltain NIH-apuraha/sopimus)

Yksittäisten osallistujien tietojen suunnitelma (IPD)

Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?

JOO

IPD-suunnitelman kuvaus

The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Lääke- ja laitetiedot, tutkimusasiakirjat

Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta

Joo

Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta

Ei

Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .

Tilaa